triazoles has been researched along with Idiopathic Parkinson Disease in 43 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.33) | 18.2507 |
| 2000's | 15 (34.88) | 29.6817 |
| 2010's | 24 (55.81) | 24.3611 |
| 2020's | 3 (6.98) | 2.80 |
| Authors | Studies |
|---|---|
| Bucolo, F; Cuzzocrea, S; De Luca, L; Di Paola, R; Gitto, R; Peña-Díaz, S; Siracusa, R; Ventura, S; Vittorio, S | 1 |
| Byeon, JJ; Choi, JM; Kim, N; Lee, BI; Lim, JH; Na, YG; Park, MH; Park, MJ; Park, SJ; Park, Y; Shin, SH; Shin, YG | 1 |
| Adornato, I; De Luca, L; Gitto, R; Peña-Díaz, S; Ventura, S; Vittorio, S | 1 |
| Capece, R; Hauser, RA; Hewitt, DJ; Ho, TW; Huyck, S; Lines, C; Michelson, D; Rascol, O; Sklar, P; Stocchi, F; Tzontcheva, A | 1 |
| Ishibashi, K; Ishii, K; Ishiwata, K; Miura, Y; Toyohara, J; Wagatsuma, K | 1 |
| Cantillon, M; Factor, SA; Hauser, RA; Ho, TW; Huyck, S; Pourcher, E; Togasaki, DM; Wolski, K | 1 |
| Bartoccini, F; Borsini, F; Cabri, W; Lucarini, S; Minetti, P; Piersanti, G; Riccioni, T; Stasi, MA; Tarzia, G | 1 |
| Bencivelli, D; Borea, PA; Casetta, I; Corciulo, C; Gentile, M; Granieri, E; Varani, K; Vincenzi, F | 1 |
| Grauer, SM; Hodgson, R; Hyde, LA | 1 |
| Alagille, D; Barret, O; Fowles, K; Hannestad, J; Laruelle, M; Lee, H; Morley, T; Papin, C; Seibyl, J; Tamagnan, G; Tavares, A; Tytgat, D; Vala, C | 1 |
| Borroto-Escuela, DO; Franco, R; Fuxe, K; Navarro, G | 1 |
| Capece, R; Hauser, RA; Hewitt, D; Ho, TW; Huyck, SB; Lines, C; Michelson, D; Rascol, O; Sklar, P; Stocchi, F | 1 |
| Bezard, E; Carta, M; Costa, G; Fidalgo, C; Ko, WK; Li, Q; Morelli, M; Pinna, A; Simola, N; Tabrizi, MA; Tronci, E | 1 |
| Adachi, N; Hattori, N; Hewitt, D; Huyck, S; Kikuchi, M; Saito, T | 1 |
| Kitaguchi, H; Kuriyama, A; Shindo, K; Tabata, H; Yamao, F | 1 |
| Boyle, CD; Chackalamannil, S; Cohen-Williams, ME; Greenlee, WJ; Higgins, GA; Lachowicz, JE; Lankin, CM; Neustadt, BR; Ng, K; Shah, U; Varty, GB; Zhang, H | 1 |
| Arik, L; Boyle, CD; Chackalamannil, S; Foster, C; Greenlee, WJ; Lachowicz, JE; Lindo, N; Monopoli, A; Neustadt, BR; Ng, K; Shah, U; Wang, S; Zhai, Y | 1 |
| Arik, L; Bertorelli, R; Cohen-Williams, M; Foster, C; Fredduzzi, S; Greenlee, WJ; Hao, J; Lachowicz, J; Liu, H; Neustadt, BR; Ng, K; Stamford, AW; Varty, G; Zhang, H | 1 |
| Goode, T; Harris, A; Trevitt, J; Vallance, C | 1 |
| Castrén, E; Gyárfás, T; Knuuttila, J; Lindholm, P; Rantamäki, T | 1 |
| Pinna, A | 1 |
| Pramanik, BN; Zhang, LK | 1 |
| Cristalli, G; Morelli, M; Pinna, A; Pontis, S; Schintu, N; Simola, N; Tronci, E; Volpini, R | 1 |
| Ahmed, MA; Alkskas, IA; Azam, F; El-gnidi, BA | 1 |
| Che, PL; Du, J; Ha, B; Wang, Z; Yarema, KJ | 1 |
| Cantillon, M; Hauser, RA; Huyck, S; Micheli, F; Mok, V; Onofrj, M; Pourcher, E; Wolski, K | 1 |
| Kincses, ZT; Szabó, N; Vécsei, L | 1 |
| Arnau, JM; Ciruela, F; Fernandez-Duenas, V; Pedros, C; Vallano, A | 1 |
| Amalric, M; Blobaum, AL; Bode, J; Bridges, TM; Bubser, M; Conn, PJ; Daniels, JS; Dickerson, JW; Engers, DW; Hopkins, CR; Italiano, K; Jadhav, S; Jones, CK; Lindsley, CW; Morrison, RD; Niswender, CM; Thompson, AD; Turle-Lorenzo, N | 1 |
| Chancellor, MB; de Groat, WC; Kitta, T; Kuno, S; Nonomura, K; Yoshimura, N | 1 |
| Cutler, DL; Grachev, ID; Tendolkar, A | 1 |
| Codd, R; Crouch, PJ; Ganio, G; Liddell, JR; Liu, J; Mok, SS; Obando, D; Volitakis, I; White, AR | 1 |
| Avila, A; Bello, J; Cardona, X; Maho, P; Martin-Baranera, M; Sastre, F | 1 |
| Fredholm, BB; Svenningsson, P | 1 |
| Gianfriddo, M; Melani, A; Pedata, F; Pugliese, AM | 1 |
| Agnati, LF; Antonelli, T; Ferraro, L; Ferré, S; Franco, R; Fuxe, K; Kehr, J; Sandager Nielsen, K; Scheel-Krüger, J; Tanganelli, S | 1 |
| Bohnert, T; Chang, H; Engber, TM; Ensinger, CL; Huang, C; Kumaravel, G; Peng, H; Petter, RC; Sha, L; Van Vlijmen, H; Vu, CB; Wang, J; Whalley, ET; Yao, G | 1 |
| Chang, H; Conlon, PR; Engber, TM; Haque, S; Kiesman, WF; Kumaravel, G; Petter, RC; Sha, L; Wang, J; Whalley, ET; Yao, G | 1 |
| Baraldi, PG; Fenu, S; Morelli, M; Simola, N; Tabrizi, MA | 1 |
| Asai, M; Matsuya, T; Miyoshi, S; Mizoguchi, H; Murakami, Y; Nagai, T; Nishimura, S; Noda, A; Sato, K; Takuma, K; Yamada, K | 1 |
| Borsini, F; Morelli, M; Pinna, A; Pontis, S | 1 |
| Benazzi, F | 1 |
| Pèzzola, A; Popoli, P; Reggio, R | 1 |
5 review(s) available for triazoles and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Purinergic signaling in Parkinson's disease. Relevance for treatment.
Topics: Adenosine; Adenosine A2 Receptor Antagonists; Animals; Basal Ganglia; Corpus Striatum; Humans; Parkinson Disease; Purine Nucleotides; Purines; Pyrimidines; Receptor, Adenosine A2A; Receptors, Dopamine D2; Signal Transduction; Triazoles | 2016 |
Novel investigational adenosine A2A receptor antagonists for Parkinson's disease.
Topics: Adenine; Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease Models, Animal; Humans; Parkinson Disease; Pyrimidines; Triazoles | 2009 |
Novel therapy in Parkinson's disease: adenosine A(2A) receptor antagonists.
Topics: Adenosine A2 Receptor Antagonists; Animals; Central Nervous System; Clinical Trials as Topic; Dopamine; Humans; Neuroprotective Agents; Parkinson Disease; Purines; Pyrimidines; Receptor, Adenosine A2A; Triazoles | 2011 |
An update on adenosine A2A receptors as drug target in Parkinson's disease.
Topics: Adenosine A2 Receptor Antagonists; Humans; Molecular Targeted Therapy; Parkinson Disease; Purines; Pyrimidines; Receptor, Adenosine A2A; Triazoles | 2011 |
Adenosine-dopamine interactions: development of a concept and some comments on therapeutic possibilities.
Topics: Adenosine; Adenosine A2 Receptor Antagonists; Animals; Caffeine; Corpus Striatum; Dopamine; Dopamine and cAMP-Regulated Phosphoprotein 32; Humans; Mice; Nerve Tissue Proteins; Parkinson Disease; Phosphoproteins; Phosphorylation; Pyrimidines; Receptor, Adenosine A2A; Receptors, Dopamine D2; Signal Transduction; Triazoles | 2003 |
8 trial(s) available for triazoles and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Randomized trial of preladenant, given as monotherapy, in patients with early Parkinson disease.
Topics: Activities of Daily Living; Adenosine A2 Receptor Antagonists; Antiparkinson Agents; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Indans; Internationality; Male; Middle Aged; Motor Activity; Parkinson Disease; Pyrimidines; Severity of Illness Index; Treatment Failure; Triazoles | 2017 |
Occupancy of adenosine A
Topics: Adenosine A2 Receptor Antagonists; Aged; Aged, 80 and over; Antiparkinson Agents; Brain; Brain Mapping; Carbon Radioisotopes; Dose-Response Relationship, Drug; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Parkinson Disease; Positron-Emission Tomography; Purines; Pyrimidines; Radiopharmaceuticals; Receptor, Adenosine A2A; Triazoles | 2018 |
Long-term safety and efficacy of preladenant in subjects with fluctuating Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Longitudinal Studies; Middle Aged; Parkinson Disease; Pyrimidines; Severity of Illness Index; Triazoles | 2013 |
Preladenant as an Adjunctive Therapy With Levodopa in Parkinson Disease: Two Randomized Clinical Trials and Lessons Learned.
Topics: Aged; Antiparkinson Agents; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; International Cooperation; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Pyrimidines; Severity of Illness Index; Time Factors; Treatment Outcome; Triazoles | 2015 |
Adjunctive preladenant: A placebo-controlled, dose-finding study in Japanese patients with Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Japan; Male; Middle Aged; Parkinson Disease; Pyrimidines; Severity of Illness Index; Time Factors; Treatment Outcome; Triazoles | 2016 |
Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Parkinson Disease; Pyrimidines; Triazoles | 2011 |
Safety, tolerability and pharmacokinetics after single and multiple doses of preladenant (SCH420814) administered in healthy subjects.
Topics: Adolescent; Adult; Area Under Curve; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Fasting; Humans; Male; Middle Aged; Parkinson Disease; Pyrimidines; Triazoles; Young Adult | 2012 |
Does nefazodone improve both depression and Parkinson disease? A pilot randomized trial.
Topics: Aged; Analysis of Variance; Depression; Female; Humans; Male; Middle Aged; Parkinson Disease; Pilot Projects; Piperazines; Prospective Studies; Single-Blind Method; Triazoles | 2003 |
30 other study(ies) available for triazoles and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Discovery of Neuroprotective Agents Based on a 5-(4-Pyridinyl)-1,2,4-triazole Scaffold.
Topics: alpha-Synuclein; Dopaminergic Neurons; Humans; Neuroprotective Agents; Parkinson Disease; Triazoles | 2022 |
In Vitro, In Silico, and In Vivo Assessments of Pharmacokinetic Properties of ZM241385.
Topics: Adenosine A2 Receptor Antagonists; Animals; Computer Simulation; Male; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Triazines; Triazoles | 2020 |
Rational design of small molecules able to inhibit α-synuclein amyloid aggregation for the treatment of Parkinson's disease.
Topics: alpha-Synuclein; Amines; Dose-Response Relationship, Drug; Drug Design; Humans; Molecular Structure; Neuroprotective Agents; Parkinson Disease; Protein Aggregates; Small Molecule Libraries; Structure-Activity Relationship; Triazoles | 2020 |
Synthesis and biological evaluation of metabolites of 2-n-butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine (ST1535), a potent antagonist of the A2A adenosine receptor for the treatment of Parkinson's disease.
Topics: Adenine; Adenosine A2 Receptor Antagonists; Animals; Behavior, Animal; Binding, Competitive; CHO Cells; Cricetinae; Cricetulus; HEK293 Cells; Humans; Mice; Models, Chemical; Molecular Structure; Parkinson Disease; Radioligand Assay; Receptor, Adenosine A2A; Time Factors; Triazoles | 2013 |
A(2A) adenosine receptors and Parkinson's disease severity.
Topics: Adenosine A2 Receptor Agonists; Aged; Disease Progression; Dose-Response Relationship, Drug; Dyskinesias; Female; Humans; Lymphocytes; Male; Middle Aged; Parkinson Disease; Protein Binding; Receptor, Adenosine A2A; Statistics, Nonparametric; Triazines; Triazoles; Tritium | 2014 |
MitoPark mice, an animal model of Parkinson's disease, show enhanced prepulse inhibition of acoustic startle and no loss of gating in response to the adenosine A(2A) antagonist SCH 412348.
Topics: Adenosine A2 Receptor Antagonists; Aging; Animals; Apomorphine; Benzothiazoles; Disease Models, Animal; Dopamine Agonists; Male; Mice; Mice, Transgenic; Motor Activity; Parkinson Disease; Pramipexole; Prepulse Inhibition; Pyrimidines; Triazoles | 2014 |
Adenosine 2A receptor occupancy by tozadenant and preladenant in rhesus monkeys.
Topics: Animals; Benzothiazoles; Brain; Chromatography, High Pressure Liquid; Disease Models, Animal; Heterocyclic Compounds, 3-Ring; Humans; Macaca mulatta; Parkinson Disease; Positron-Emission Tomography; Pyrimidines; Radiometry; Receptor, Adenosine A2A; Time Factors; Triazoles; Whole Body Imaging | 2014 |
Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Male; Parkinson Disease; Piperazines; Pyrimidines; Rats; Rats, Sprague-Dawley; Serotonin Receptor Agonists; Triazoles | 2016 |
Suvorexant-Induced Dream Enactment Behavior in Parkinson Disease: A Case Report.
Topics: Aged; Azepines; Dreams; Humans; Male; Parasomnias; Parkinson Disease; Sleep Aids, Pharmaceutical; Sleep Initiation and Maintenance Disorders; Triazoles | 2017 |
Design, synthesis, and evaluation of fused heterocyclic analogs of SCH 58261 as adenosine A2A receptor antagonists.
Topics: Adenosine; Adenosine A2 Receptor Antagonists; Administration, Oral; Animals; Area Under Curve; Chemistry, Pharmaceutical; Disease Models, Animal; Drug Design; Hydrogen-Ion Concentration; Models, Chemical; Parkinson Disease; Pyrimidines; Rats; Solubility; Triazoles; Water | 2008 |
Biaryl and heteroaryl derivatives of SCH 58261 as potent and selective adenosine A2A receptor antagonists.
Topics: Adenosine A2 Receptor Antagonists; Administration, Oral; Animals; Behavior, Animal; Chemistry, Pharmaceutical; Drug Design; Humans; Models, Chemical; Neuroprotective Agents; Parkinson Disease; Piperazines; Pyrimidines; Quinolines; Rats; Structure-Activity Relationship; Triazoles | 2008 |
Potent and selective adenosine A2A receptor antagonists: 1,2,4-Triazolo[1,5-c]pyrimidines.
Topics: Adenosine A2 Receptor Antagonists; Administration, Oral; Animals; Area Under Curve; Catalepsy; Chemistry, Pharmaceutical; Drug Design; Haloperidol; Models, Chemical; Parkinson Disease; Pyrimidines; Rats; Structure-Activity Relationship; Triazoles | 2009 |
Adenosine antagonists reverse the cataleptic effects of haloperidol: implications for the treatment of Parkinson's disease.
Topics: Animals; Caffeine; Catalepsy; Dose-Response Relationship, Drug; Haloperidol; Male; Parkinson Disease; Purinergic P1 Receptor Antagonists; Pyrimidines; Rats; Rats, Sprague-Dawley; Triazoles | 2009 |
Regulation of brain-derived neurotrophic factor (BDNF) and cerebral dopamine neurotrophic factor (CDNF) by anti-parkinsonian drug therapy in vivo.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Blotting, Western; Brain; Brain-Derived Neurotrophic Factor; Corpus Striatum; Cytoprotection; Gyrus Cinguli; Male; Mice; Mice, Inbred C57BL; Monoamine Oxidase Inhibitors; Nerve Growth Factors; Neuroprotective Agents; Parkinson Disease; Pyrimidines; Receptor, Adenosine A2A; Selegiline; Triazoles; Up-Regulation | 2010 |
Characterization of major degradation products of an adenosine A2A receptor antagonist under stressed conditions by LC-MS and FT tandem MS analysis.
Topics: Adenosine A2 Receptor Antagonists; Chromatography, High Pressure Liquid; Drug Stability; Fourier Analysis; Humans; Molecular Structure; Oxidation-Reduction; Parkinson Disease; Pyrimidines; Tablets; Tandem Mass Spectrometry; Triazoles | 2010 |
A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenine; Animals; Antiparkinson Agents; Autoradiography; Behavior, Animal; Brain Chemistry; CD11b Antigen; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Early Growth Response Protein 1; Gene Expression Regulation; Jaw; Levodopa; Male; Mice; Mice, Inbred C57BL; Motor Activity; Movement; Nerve Degeneration; Nerve Tissue Proteins; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Psychomotor Performance; Pyrimidines; Rats; Rats, Sprague-Dawley; RNA, Messenger; Rotarod Performance Test; Time Factors; Triazoles; Vibrissae | 2010 |
Design, synthesis and anti-Parkinsonian evaluation of 3-alkyl/aryl-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidine-2(3H)-thiones against neuroleptic-induced catalepsy and oxidative stress in mice.
Topics: Animals; Antiparkinson Agents; Antipsychotic Agents; Biomarkers; Brain; Catalepsy; Computational Biology; Drug Design; Furans; Glutathione; Lipid Peroxidation; Male; Mice; Molecular Structure; Neuroprotective Agents; Oxidative Stress; Oxidoreductases; Parkinson Disease; Pyrimidines; Specific Pathogen-Free Organisms; Thiones; Triazoles | 2010 |
Static magnetic field exposure reproduces cellular effects of the Parkinson's disease drug candidate ZM241385.
Topics: Adenosine; Adenosine A2 Receptor Agonists; Adenosine A2 Receptor Antagonists; Adenosine Triphosphate; Analysis of Variance; Animals; Blotting, Western; Calcium; Cell Proliferation; Cyclic AMP; Iron; Magnetic Field Therapy; Magnetics; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neurites; Parkinson Disease; PC12 Cells; Phenethylamines; Phosphorylation; Rats; Receptor, Adenosine A2A; Triazines; Triazoles | 2010 |
The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenosine A2 Receptor Antagonists; Animals; Brain; Calcium Signaling; Catalepsy; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; G Protein-Coupled Inwardly-Rectifying Potassium Channels; Glutamic Acid; Haloperidol; HEK293 Cells; Humans; Levodopa; Male; Monoamine Oxidase; Motor Neuron Disease; Oxidopamine; Parkinson Disease; Picolinic Acids; Protein Binding; Psychomotor Performance; Pyrimidines; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reaction Time; Receptors, G-Protein-Coupled; Receptors, Metabotropic Glutamate; Substantia Nigra; Thallium; Transfection; Triazoles; Tyrosine 3-Monooxygenase | 2012 |
Suppression of bladder overactivity by adenosine A2A receptor antagonist in a rat model of Parkinson disease.
Topics: Adenosine A2 Receptor Antagonists; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Parkinson Disease; Rats; Rats, Sprague-Dawley; Triazines; Triazoles; Urinary Bladder, Overactive; Urination | 2012 |
Lipophilic adamantyl- or deferasirox-based conjugates of desferrioxamine B have enhanced neuroprotective capacity: implications for Parkinson disease.
Topics: Adamantane; Animals; Astrocytes; Benzoates; Cells, Cultured; Deferasirox; Deferoxamine; Dopaminergic Neurons; Humans; Hydrogen Peroxide; Iron Chelating Agents; Mice; Neuroprotective Agents; Oxidative Stress; Parkinson Disease; Permeability; Substantia Nigra; Triazoles | 2013 |
A2A receptors in neuroprotection of dopaminergic neurons.
Topics: Adenosine A2 Receptor Antagonists; Animals; Caffeine; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Humans; Male; Neurons; Neuroprotective Agents; Parkinson Disease; Purines; Pyrimidines; Receptor, Adenosine A2A; Sex Factors; Triazoles | 2003 |
Striatal plasticity at the network level. Focus on adenosine A2A and D2 interactions in models of Parkinson's Disease.
Topics: Adenosine A2 Receptor Antagonists; Animals; Corpus Striatum; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Female; Levodopa; Male; Mice; Nerve Net; Neuronal Plasticity; Parkinson Disease; Pyrimidines; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptor, Adenosine A2A; Receptors, Dopamine D2; Triazoles | 2004 |
Novel bicyclic piperazine derivatives of triazolotriazine and triazolopyrimidines as highly potent and selective adenosine A2A receptor antagonists.
Topics: Adenosine A2 Receptor Antagonists; Administration, Oral; Animals; Catalepsy; Disease Models, Animal; Drug Stability; In Vitro Techniques; Male; Mice; Microsomes, Liver; Molecular Structure; Parkinson Disease; Piperazines; Pyrimidines; Radioligand Assay; Rats; Rats, Sprague-Dawley; Stereoisomerism; Structure-Activity Relationship; Triazines; Triazoles | 2004 |
Synthesis of alkyne derivatives of a novel triazolopyrazine as A(2A) adenosine receptor antagonists.
Topics: Adenosine A2 Receptor Antagonists; Administration, Oral; Alkynes; Animals; Catalepsy; Cerebral Cortex; Disease Models, Animal; Mice; Oxidopamine; Parkinson Disease; Pyrazines; Rats; Structure-Activity Relationship; Triazoles | 2005 |
Dopamine and adenosine receptor interaction as basis for the treatment of Parkinson's disease.
Topics: Analysis of Variance; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Interactions; Jaw; Male; Movement; Parkinson Disease; Pilocarpine; Piperazines; Purinergic P1 Receptor Antagonists; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptors, Purinergic P1; Tacrine; Tremor; Triazoles | 2006 |
Synergistic effects of adenosine A2A antagonist and L-DOPA on rotational behaviors in 6-hydroxydopamine-induced hemi-Parkinsonian mouse model.
Topics: Adenosine A2 Receptor Antagonists; Adrenergic Agents; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Drug Synergism; Levodopa; Male; Mice; Mice, Inbred ICR; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Pyrimidines; Receptor, Adenosine A2A; Rotation; Triazoles | 2007 |
Adenosine A2A receptor antagonists improve deficits in initiation of movement and sensory motor integration in the unilateral 6-hydroxydopamine rat model of Parkinson's disease.
Topics: Adenine; Adenosine A2 Receptor Antagonists; Animals; Dihydroxyphenylalanine; Dopamine Agents; Functional Laterality; Immunohistochemistry; Levodopa; Male; Neuroprotective Agents; Parkinson Disease; Psychomotor Performance; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Triazoles; Tyrosine 3-Monooxygenase; Vibrissae | 2007 |
Parkinson's disease worsened by nefazodone.
Topics: Aged; Antidepressive Agents, Second-Generation; Depression; Humans; Male; Parkinson Disease; Parkinson Disease, Secondary; Piperazines; Selective Serotonin Reuptake Inhibitors; Triazoles | 1997 |
Effects of SCH 58261, an adenosine A(2A) receptor antagonist, on quinpirole-induced turning in 6-hydroxydopamine-lesioned rats. Lack of tolerance after chronic caffeine intake.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Behavior, Animal; Caffeine; Central Nervous System Stimulants; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Tolerance; Male; Motor Activity; Neuroprotective Agents; Parkinson Disease; Purinergic P1 Receptor Antagonists; Pyrimidines; Quinpirole; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Time Factors; Triazoles | 2000 |